454 related articles for article (PubMed ID: 27269043)
21. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials.
Lipton RB; Singh RBH; Revicki DA; Zhao S; Shewale AR; Lateiner JE; Dodick DW
J Headache Pain; 2022 Apr; 23(1):50. PubMed ID: 35468729
[TBL] [Abstract][Full Text] [Related]
22. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
24. Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.
Li CC; Voss T; Kowalski K; Yang B; Kleijn HJ; Jones CJ; Bosch R; Michelson D; DeAngelis M; Xu Y; Xie I; Kothare PA
Clin Transl Sci; 2020 May; 13(3):482-490. PubMed ID: 31758661
[TBL] [Abstract][Full Text] [Related]
25. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.
Ho TW; Mannix LK; Fan X; Assaid C; Furtek C; Jones CJ; Lines CR; Rapoport AM;
Neurology; 2008 Apr; 70(16):1304-12. PubMed ID: 17914062
[TBL] [Abstract][Full Text] [Related]
26. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
Marcus R; Goadsby PJ; Dodick D; Stock D; Manos G; Fischer TZ
Cephalalgia; 2014 Feb; 34(2):114-25. PubMed ID: 23965396
[TBL] [Abstract][Full Text] [Related]
27. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
Blumenfeld AM; Knievel K; Manack Adams A; Severt L; Butler M; Lai H; Dodick DW
Adv Ther; 2022 Jan; 39(1):692-705. PubMed ID: 34874514
[TBL] [Abstract][Full Text] [Related]
28. Ubrogepant: First Approval.
Scott LJ
Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
[TBL] [Abstract][Full Text] [Related]
30. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.
Ankrom W; Bondiskey P; Li CC; Palcza J; Liu W; Dockendorf MF; Matthews C; Panebianco D; Reynders T; Wagner JA; Jakate A; Mesens S; Kraft WK; Marcantonio EE
Clin Transl Sci; 2020 May; 13(3):462-472. PubMed ID: 31899602
[TBL] [Abstract][Full Text] [Related]
31. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
Connor KM; Shapiro RE; Diener HC; Lucas S; Kost J; Fan X; Fei K; Assaid C; Lines C; Ho TW
Neurology; 2009 Sep; 73(12):970-7. PubMed ID: 19770473
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
Lipton RB; Dodick DW; Goadsby PJ; Burstein R; Adams AM; Lai J; Yu SY; Finnegan M; Kuang AW; Trugman JM
Neurology; 2022 Oct; 99(17):e1905-e1915. PubMed ID: 35977836
[TBL] [Abstract][Full Text] [Related]
33. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine.
Hewitt DJ; Aurora SK; Dodick DW; Goadsby PJ; Ge YJ; Bachman R; Taraborelli D; Fan X; Assaid C; Lines C; Ho TW
Cephalalgia; 2011 Apr; 31(6):712-22. PubMed ID: 21383045
[TBL] [Abstract][Full Text] [Related]
34. Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.
Joyner KR; Morgan KW
Ann Pharmacother; 2021 Jun; 55(6):745-759. PubMed ID: 32993366
[TBL] [Abstract][Full Text] [Related]
35. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ
N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516
[TBL] [Abstract][Full Text] [Related]
36. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
Yu S; Guo A; Wang Z; Liu J; Tan G; Yang Q; Zhang M; Yibulaiyin H; Chen H; Zhang Y; Croop R; Sun Y; Liu Y; Zhao Q; Lu Z
J Headache Pain; 2024 Apr; 25(1):57. PubMed ID: 38627638
[TBL] [Abstract][Full Text] [Related]
37. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials.
Hutchinson S; Dodick DW; Treppendahl C; Bennett NL; Yu SY; Guo H; Trugman JM
Neurol Ther; 2021 Jun; 10(1):235-249. PubMed ID: 33608814
[TBL] [Abstract][Full Text] [Related]
38. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
Dodick DW; Kost J; Assaid C; Lines C; Ho TW
Cephalalgia; 2011 Feb; 31(3):296-300. PubMed ID: 20937606
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
MacGregor EA; Hutchinson S; Lai H; Dabruzzo B; Yu SY; Trugman JM; Ailani J
Headache; 2023 Sep; 63(8):1135-1144. PubMed ID: 37655536
[TBL] [Abstract][Full Text] [Related]
40. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
